| 摘要 |
<p>This patent deals with a solution related to 2,6- -substituted 3-[[2'-(1H-tetrazol-5-yl)[1,1'-bipehnyl]-4- -yl]methyl-4(3H)-quinazoline compound with general formula (I), where X is direct or branched alkyl, n is 1 up to 3, R6 is a group with a formula (i), (ii), (iii), (iv), (v), (vi), (vii) or (viii), where R9 is H, alkyl with a direct chain phenyl, mono substituted phenyl, where a substituent is selected of the group including alkyl, -CF3, nitro, O-alkyl or -NH2, and also pyridine or thiophene or furan, R10 is H, alkyl with a direct chain, phenyl monosubstituted phenyl, where the substituent is selected of the group which includes alkyl, -CF3, nitro, O-alkyl or -NH2 and pyridine, thiophene or furan, however there is a condition that R9 and R10 cannot mean hydrogen simultaneously, R11 is H, alkyl R12 with a direct chain, phenyl monosubstisturted phenyl, where the substituent is selected of the group containing alkyl, -CF3, nitro, O-alkyl or -NH2 and pyridine, thiophene or furane, R17 is alkyl or salts acceptable form pharmaceutical point of view, while this patent describes intermediate products for preparation of this compound prepared based on this compound. The compound with a general formula (I) has a higher efficiency of antagonists of angiothesine II.</p> |
